Join us at our 2024 Patient Conference on July 26th! You will have an opportunity to meet and mingle with patients, as well as learn from top CCM researchers. More details coming soon! We also have social activities lined up for anyone planning to stick around on Saturday. Location: SickKids Hospital Peter Gilgan Centre for…
We are excited to announce that we have updated our patient registry to a new platform! There are two options to create an account in our new registry: Patient account-this is for affected individuals 18 years or older Caregiver account-this is for parents or legal guardians of a minor-age affected person OR a legal representative…
We are thrilled to announce that the Phase 2 safety trial of Recursion’s REC-994 medicine, being developed specifically for symptomatic CCM, has fully enrolled 60 patients ahead of schedule. Our thanks to all of our members who are participating in this first-ever industry-sponsored trial. You made this enrollment a success, and we are so proud…
Learn more about how clinical trials work, check out some Myths vs Facts and get your questions answered with our FAQs. Still have more questions? Reach out at ClinicalTrials@AllianceToCure.org
August 1, 2022 – The atorvastatin experimental proof of concept trial to treat cavernous malformations with symptomatic hemorrhage, hosted at the University of Chicago, has completed enrollment. We congratulate and are grateful to all those who are participating! Along with the atorvastatin trial, the parallel Trial Readiness project at the University of Chicago has also…
